Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

NCT05494762 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

55

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Solid Tumor

Interventions

DRUG: BGB-B167
DRUG: Tislelizumab

Sponsor

BeiGene